Skip to main
BIOA

BIOA Stock Forecast & Price Target

BIOA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Bioage Labs is well positioned for success due to their innovative approach to targeting the biology of human aging, evidenced by their promising drug, BGE-102, and their focus on developing therapeutic products for metabolic diseases. The company's strategic partnerships and continued development of other potential treatments for obesity and ophthalmology demonstrate their commitment to sustained growth and expansion in the biopharmaceutical industry. With solid financials and promising clinical results, Bioage Labs is an attractive investment for those looking to capitalize on the rapidly growing field of anti-aging therapeutics.

Bears say

Bioage Labs is a biopharmaceutical company with a promising pipeline of treatments for metabolic diseases based on longitudinal human data. While their recent financial statement and enrollment progress are positive indicators, the risk of liver toxicity in early drug development and previous setbacks with VTX3232 are concerning. However, with multiple partnerships and a potential for identifying new targets, Bioage Labs has the potential for long-term success in the future.

BIOA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioAge Labs Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioAge Labs Inc (BIOA) Forecast

Analysts have given BIOA a Buy based on their latest research and market trends.

According to 8 analysts, BIOA has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioAge Labs Inc (BIOA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.